Skip to main content
NCBI home page
British Heart Journal logoLink to British Heart Journal
. 1985 Apr;53(4):431–435. doi: 10.1136/hrt.53.4.431

Haemodynamic and neurohumoral response to exercise in patients with congestive heart failure treated with captopril.

M A Creager, D P Faxon, D A Weiner, T J Ryan
PMCID: PMC481784  PMID: 3885981

Abstract

The contribution of the renin-angiotensin system to the cardiovascular response to exercise was studied in 12 patients with congestive heart failure. The haemodynamic effects of captopril were measured at rest and during supine bicycle exercise. After captopril administration, resting systemic vascular resistance fell by 26.6% and mean blood pressure by 16.7% and cardiac index increased by 19.7%. During exercise, captopril decreased systemic vascular resistance by 25.6% and mean blood pressure by 8.2% and increased cardiac index by 24.4%. Pulmonary wedge pressure fell by 25% at rest but was not altered by captopril during exercise. Pretreatment plasma renin activity increased from 13.4(16.0) ng/ml/hr (10.3(12.3) mmol/l/hr) at rest to 20.0(27.8) ng/ml/hr (15.4(21.4) mmol/l/hr) during exercise. Pretreatment plasma noradrenaline concentration increased from 659(433) pg/ml (39(25.6) nmol/l) at rest to 2622(1486) pg/ml during exercise (155(88) nmol/l). Captopril favourably alters systemic vascular resistance and cardiac index during exercise in patients with congestive heart failure. This may reflect inhibition of the increased activity of the renin-angiotensin system during exercise in these patients and a subsequent reduction in systemic vasoconstriction.

Full text

PDF
431

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ader R., Chatterjee K., Ports T., Brundage B., Hiramatsu B., Parmley W. Immediate and sustained hemodynamic and clinical improvement in chronic heart failure by an oral angiotensin-converting enzyme inhibitor. Circulation. 1980 May;61(5):931–937. doi: 10.1161/01.cir.61.5.931. [DOI] [PubMed] [Google Scholar]
  2. Ben-Jonathan N., Porter J. C. A sensitive radioenzymatic assay for dopamine, norepinephrine, and epinephrine in plasma and tissue. Endocrinology. 1976 Jun;98(6):1497–1507. doi: 10.1210/endo-98-6-1497. [DOI] [PubMed] [Google Scholar]
  3. CHIDSEY C. A., HARRISON D. C., BRAUNWALD E. Augmentation of the plasma nor-epinephrine response to exercise in patients with congestive heart failure. N Engl J Med. 1962 Sep 27;267:650–654. doi: 10.1056/NEJM196209272671305. [DOI] [PubMed] [Google Scholar]
  4. Cody R. J., Covit A. B., Schaer G. L., Laragh J. H. Evaluation of a long-acting converting enzyme inhibitor (enalapril) for the treatment of chronic congestive heart failure. J Am Coll Cardiol. 1983 Apr;1(4):1154–1159. doi: 10.1016/s0735-1097(83)80119-3. [DOI] [PubMed] [Google Scholar]
  5. Creager M. A., Faxon D. P., Rockwell S. M., Melby J. C., Gavras H., Coffman J. D. Effect of renin-angiotensin system on limb circulation in normal subjects. Am J Physiol. 1984 Feb;246(2 Pt 2):H239–H244. doi: 10.1152/ajpheart.1984.246.2.H239. [DOI] [PubMed] [Google Scholar]
  6. Creager M. A., Halperin J. L., Bernard D. B., Faxon D. P., Melidossian C. D., Gavras H., Ryan T. J. Acute regional circulatory and renal hemodynamic effects of converting-enzyme inhibition in patients with congestive heart failure. Circulation. 1981 Sep;64(3):483–489. doi: 10.1161/01.cir.64.3.483. [DOI] [PubMed] [Google Scholar]
  7. Curtiss C., Cohn J. N., Vrobel T., Franciosa J. A. Role of the renin-angiotensin system in the systemic vasoconstriction of chronic congestive heart failure. Circulation. 1978 Nov;58(5):763–770. doi: 10.1161/01.cir.58.5.763. [DOI] [PubMed] [Google Scholar]
  8. Davis R., Ribner H. S., Keung E., Sonnenblick E. H., LeJemtel T. H. Treatment of chronic congestive heart failure with captopril, an oral inhibitor of angiotensin-converting enzyme. N Engl J Med. 1979 Jul 19;301(3):117–121. doi: 10.1056/NEJM197907193010301. [DOI] [PubMed] [Google Scholar]
  9. DiCarlo L., Chatterjee K., Parmley W. W., Swedberg K., Atherton B., Curran D., Cucci M. Enalapril: a new angiotensin-converting enzyme inhibitor in chronic heart failure: acute and chronic hemodynamic evaluations. J Am Coll Cardiol. 1983 Nov;2(5):865–871. doi: 10.1016/s0735-1097(83)80233-2. [DOI] [PubMed] [Google Scholar]
  10. Dzau V. J., Colucci W. S., Williams G. H., Curfman G., Meggs L., Hollenberg N. K. Sustained effectiveness of converting-enzyme inhibition in patients with severe congestive heart failure. N Engl J Med. 1980 Jun 19;302(25):1373–1379. doi: 10.1056/NEJM198006193022501. [DOI] [PubMed] [Google Scholar]
  11. Engel S. L., Schaeffer T. R., Gold B. I., Rubin B. Inhibition of pressor effects of angiotensin I and augmentation of depressor effects of bradykinin by synthetic peptides. Proc Soc Exp Biol Med. 1972 May;140(1):240–244. doi: 10.3181/00379727-140-36433. [DOI] [PubMed] [Google Scholar]
  12. Fagard R., Amery A., Reybrouck T., Lijnen P., Moerman E., Bogaert M., De Schaepdryver A. Effects of angiotensin antagonism on hemodynamics, renin, and catecholamines during exercise. J Appl Physiol Respir Environ Exerc Physiol. 1977 Sep;43(3):440–444. doi: 10.1152/jappl.1977.43.3.440. [DOI] [PubMed] [Google Scholar]
  13. Faxon D. P., Creager M. A., Halperin J. L., Gavras H., Coffman J. D., Ryan T. J. Central and peripheral hemodynamic effects of angiotensin inhibition in patients with refractory congestive heart failure. Circulation. 1980 May;61(5):925–930. doi: 10.1161/01.cir.61.5.925. [DOI] [PubMed] [Google Scholar]
  14. Faxon D. P., Halperin J. L., Creager M. A., Gavras H., Schick E. C., Ryan T. J. Angiotensin inhibition in severe heart failure: acute central and limb hemodynamic effects of captopril with observations on sustained oral therapy. Am Heart J. 1981 May;101(5):548–556. doi: 10.1016/0002-8703(81)90220-9. [DOI] [PubMed] [Google Scholar]
  15. Francis G. S., Goldsmith S. R., Ziesche S. M., Cohn J. N. Response of plasma norepinephrine and epinephrine to dynamic exercise in patients with congestive heart failure. Am J Cardiol. 1982 Apr 1;49(5):1152–1156. doi: 10.1016/0002-9149(82)90039-x. [DOI] [PubMed] [Google Scholar]
  16. Gavras H., Flessas A., Ryan T. J., Brunner H. R., Faxon D. P., Gavras I. Angiotensin II inhibition. Treatment of congestive cardiac failure in a high-renin hypertension. JAMA. 1977 Aug 22;238(8):880–882. doi: 10.1001/jama.238.8.880. [DOI] [PubMed] [Google Scholar]
  17. Halperin J. L., Faxon D. P., Creager M. A., Bass T. A., Melidossian C. D., Gavras H., Ryan T. J. Coronary hemodynamic effects of angiotensin inhibition by captopril and teprotide in patients with congestive heart failure. Am J Cardiol. 1982 Nov;50(5):967–972. doi: 10.1016/0002-9149(82)90403-9. [DOI] [PubMed] [Google Scholar]
  18. Heyndrickx G. R., Boettcher D. H., Vatner S. F. Effects of angiotensin, vasopressin, and methoxamine on cardiac function and blood flow distribution in conscious dogs. Am J Physiol. 1976 Nov;231(5 Pt 1):1579–1587. doi: 10.1152/ajplegacy.1976.231.5.1579. [DOI] [PubMed] [Google Scholar]
  19. Kotchen T. A., Hartley L. H., Rice T. W., Mougey E. H., Jones L. G., Mason J. W. Renin, norepinephrine, and epinephrine responses to graded exercise. J Appl Physiol. 1971 Aug;31(2):178–184. doi: 10.1152/jappl.1971.31.2.178. [DOI] [PubMed] [Google Scholar]
  20. Kramer B. L., Massie B. M., Topic N. Controlled trial of captopril in chronic heart failure: a rest and exercise hemodynamic study. Circulation. 1983 Apr;67(4):807–816. doi: 10.1161/01.cir.67.4.807. [DOI] [PubMed] [Google Scholar]
  21. Levine T. B., Franciosa J. A., Cohn J. N. Acute and long-term response to an oral converting-enzyme inhibitor, captopril, in congestive heart failure. Circulation. 1980 Jul;62(1):35–41. doi: 10.1161/01.cir.62.1.35. [DOI] [PubMed] [Google Scholar]
  22. Mark A. L., Abboud F. M., Schmid P. G., Heistad D. D., Mayer H. E. Differences in direct effects of adrenergic stimuli on coronary, cutaneous, and muscular vessels. J Clin Invest. 1972 Feb;51(2):279–287. doi: 10.1172/JCI106812. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Scroop G. C., Walsh J. A., Whelan R. F. A comparison of the effects of intra-arterial and intravenous infusions of angiotensin and noradrenaline on the circulation in man. Clin Sci. 1965 Oct;29(2):315–326. [PubMed] [Google Scholar]
  24. Sealey J. E., Gerten-Banes J., Laragh J. H. The renin system: Variations in man measured by radioimmunoassay or bioassay. Kidney Int. 1972 Apr;1(4):240–253. doi: 10.1038/ki.1972.34. [DOI] [PubMed] [Google Scholar]
  25. Swartz S. L., Williams G. H., Hollenberg N. K., Levine L., Dluhy R. G., Moore T. J. Captopril-induced changes in prostaglandin production: relationship to vascular responses in normal man. J Clin Invest. 1980 Jun;65(6):1257–1264. doi: 10.1172/JCI109788. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. WOOD J. E. Peripheral venous and arteriolar responses to infusions of angiotensin in normal and hypertensive subjects. Circ Res. 1961 May;9:768–774. doi: 10.1161/01.res.9.3.768. [DOI] [PubMed] [Google Scholar]

Articles from British Heart Journal are provided here courtesy of BMJ Publishing Group

RESOURCES